Core Insights - Knight Therapeutics Inc. reported a challenging quarter with an earnings per share (EPS) of -$0.02, missing the estimated EPS of -$0.005 [2][6] - The company's actual revenue was approximately $88 million, falling short of the estimated $107 million, although it showed an increase from the previous year [3][6] - The gross margin decreased to 46% from 49% last year, primarily due to increased costs associated with the Paladin and Sumitomo deals [3][6] Financial Metrics - The price-to-sales ratio is 1.56, and the enterprise value to sales ratio is 1.63, indicating the stock is valued at about 1.56 times its sales [4] - The debt-to-equity ratio stands at 0.14, reflecting a low level of debt compared to equity, suggesting financial stability [4] - The current ratio of 2.47 indicates a strong ability to cover short-term liabilities with short-term assets, ensuring liquidity [5]
Knight Therapeutics Inc. (OTC:KHTRF) Faces Challenges but Shows Growth in Q3 2025 Earnings
Financial Modeling Prepยท2025-11-07 04:04